TRx0014 in Patients With Mild or Moderate Alzheimer's Disease
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to investigate the effects of oral TRx0014 at three
doses (30, 60 and 100 mg tid) compared with placebo on cognitive ability in patients with
mild or moderate dementia of the Alzheimer type. Cognitive ability will be measured by the
Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog). The primary evaluation
will be made at 24 weeks.